{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089813","form_type":"8-K","ticker":"HYPD","cik":"0001682639","company_name":"HYPERION DEFI, INC.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.845936+00:00","generated_at":"2026-06-11T18:11:16.267363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Eyenovia Q2 net loss narrows to $6.2M; first Mydcombi sale post-FDA approval","bullets":["Net loss for Q2 2023 was $(6.2)M ($0.16 per share), improved from $(7.2)M ($0.22) in Q2 2022; cash $17.5M as of June 30.","First commercial sale of Mydcombi to Dr. Nathan Radcliffe; national launch expected in early 2024 after FDA approval.","Apersure (Microline) presbyopia program advances; FDA provided clear path; registration batch manufacture planned for Q4 2023.","R&D expenses $2.8M (down from $3.6M), G&A $3.1M (down from $3.5M); total op expenses $6.0M vs $7.1M YoY.","Added to Russell 2000 and 3000 indexes; licensing partners Bausch+Lomb and Arctic Vision enrolling Phase 3 trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089813","json":"https://secwatch.observer/filing/0001104659-23-089813.json","markdown":"https://secwatch.observer/filing/0001104659-23-089813.md","text":"https://secwatch.observer/filing/0001104659-23-089813.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923089813/0001104659-23-089813-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923089813/tm2323259d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:11:16.267363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4700a317a3d47b432cae6de919449d035f214d4","claim":"HYPERION DEFI, INC. reported the second quarter ended June 30, 2023 results: net income approximately $(6.2) million, or $(0.16) per share, EPS $(0.16) per share.","evidence_excerpt":"On August 10, 2023, Eyenovia, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923089813/0001104659-23-089813-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"approximately $(6.2) million, or $(0.16) per share"},{"label":"EPS","value":"$(0.16) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}